Full-Time
Clinical-stage biopharma addressing genetically defined diseases
$240k/yr
Cambridge, MA, USA
In Person
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on genetically defined rare diseases. It uses a proprietary product engine to systematically identify and validate cellular drug targets and to modulate gene expression in order to address the root causes of these diseases. The company collaborates with other industry players, such as MyoKardia, to discover targeted therapies for genetic cardiomyopathies. Its business model centers on developing and commercializing therapies and earning revenue through product sales, partnerships, and licensing agreements. Unlike competitors that may have broader approaches, Fulcrum concentrates on precise genetic targets and gene-expression modulation to tackle specific rare diseases, aiming to bring real clinical benefits to patients while pursuing collaborations to expand its pipeline.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
People at Fulcrum Therapeutics who can refer or advise you
Flexible Work Hours
Hybrid Work Options
Remote Work Options
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
PTO/vacation
Fulcrum Therapeutics to participate in the 44th Annual J.P. Morgan Healthcare Conference. CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) - Fulcrum Therapeutics, Inc.(R)(Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' website for at least 30 days following the presentation. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has priced its public offering of 11.85 million common shares at $13.50 each and pre-funded warrants for 1.11 million additional shares at $13.499 per warrant. The offering is expected to raise approximately $175 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 1.94 million additional shares. Proceeds will support general corporate purposes, including research and development for clinical programmes, particularly pociredir, its lead treatment for sickle cell disease. J.P. Morgan, Leerink Partners and Cantor are serving as book-running managers, with Oppenheimer & Co. and Truist Securities also participating. The offering is expected to close on 11 December 2025, subject to customary conditions.
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company...
Fulcrum Therapeutics to present new clinical data from the PIONEER trial of pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting. Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be Hosted Onsite on Sunday, December 7 CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) - Fulcrum Therapeutics, Inc.(R)(the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that new data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting. Additionally, Fulcrum will present preclinical data highlighting its calmodulin pathway modulator program for the potential treatment of bone marrow failure syndromes. "We are looking forward to presenting new clinical data from the PIONEER trial at ASH, including full data from the 12 mg dose cohort and initial data from the 20 mg dose cohort," said Alex C. Sapir, Fulcrum's President and Chief Executive Officer. "These data will further characterize pociredir's potential as a disease-modifying therapy for sickle cell disease, and we look forward to discussing the results in greater detail during our investor event at ASH." Title: Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b PIONEER study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness
Fulcrum Therapeutics to participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.